Get the Stockscreener App
0.7426
2.98%
0.0285
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Vaxart Inc stock is traded at $0.7426, with a volume of 367.54K.
It is up +2.98% in the last 24 hours and down -12.18% over the past month.
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
See More
Previous Close:
$0.7141
Open:
$0.7
24h Volume:
367.54K
Relative Volume:
0.21
Market Cap:
$163.79M
Revenue:
$9.10M
Net Income/Loss:
$-82.47M
P/E Ratio:
-1.2803
EPS:
-0.58
Net Cash Flow:
$-72.32M
1W Performance:
+1.56%
1M Performance:
-12.18%
6M Performance:
+24.56%
1Y Performance:
-36.88%
1-Day Range:
$0.70
$0.749
1-Week Range:
$0.65
$0.749
52-Week Range:
$0.52
$1.54
Vaxart Inc Stock (VXRT) Company Profile
Name
Vaxart Inc
Sector
Industry
Phone
(650) 550-3500
Address
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VXRT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.7426 | 163.79M | 9.10M | -82.47M | -72.32M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.62 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.09 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.15 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.41 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.97 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-24 | Initiated | Oppenheimer | Outperform |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Nov-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-29-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jun-24-21 | Initiated | Jefferies | Buy |
| Jun-11-21 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
View All
Vaxart Inc Stock (VXRT) Latest News
Vaxart appoints new board member with healthcare expertise By Investing.com - Investing.com South Africa
Vaxart appoints new board member with healthcare expertise - Investing.com
Vaxart Announces Board Changes with New Appointment - TipRanks
Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors - GlobeNewswire
Vaxart (NASDAQ: VXRT) Receives Positive Recommendation for Phase 2b COVID-19 Vaccine TrialOn January 13, 2025, Vaxart, Inc. announced that an independent Data Safety Monitoring Board has recommended that the Company’s Phase 2b clinical trial - Defense World
Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving AverageTime to Sell? - MarketBeat
Vaxart (NASDAQ:VXRT) Shares Pass Below Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Vaxart advances Phase 2b COVID-19 vaccine trial By Investing.com - Investing.com Canada
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - GlobeNewswire
Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs - GlobeNewswire
Nasdaq Biotechnology Index (NBI) QuotePress Release - The Globe and Mail
Nasdaq Q-50 Index (NXTQ) QuotePress Release - The Globe and Mail
Vaxart Inc (VXRT-Q) QuotePress Release - The Globe and Mail
TSX Global Mining Index (TXGM) QuotePress Release - The Globe and Mail
TSX Global Gold EW Index (TXGE) QuotePress Release - The Globe and Mail
KBW Premium Yield Equity REIT Index (KYX) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Vaxart advances Phase 2b COVID-19 vaccine trial - Investing.com
Vaxart Advances COVID-19 Oral Vaccine to 10,000-Patient Trial, Expands Pipeline with Norovirus Program - StockTitan
Vaxart's Oral COVID Vaccine Advances: Safety Board Backs Phase 2b Trial Expansion to 10,000 Patients - StockTitan
Deutsche Bank Ag (DB-N) QuotePress Release - The Globe and Mail
Ast Spacemobile Inc (ASTS-Q) QuotePress Release - The Globe and Mail
Vaxart (STU:NB11) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
Vaxart spikes as B. Riley upgrades at long last after BARDA funding - MSN
Geode Capital Management LLC Acquires 346,725 Shares of Vaxart, Inc. (NASDAQ:VXRT) - Defense World
Andrei Floroiu Vaxart CEO Rating - Comparably Workplace Insider
Revenues Not Telling The Story For Vaxart, Inc. (NASDAQ:VXRT) After Shares Rise 47% - Simply Wall St
Vaxart Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Defense World
Vaxart (NASDAQ: VXRT) Increases Funding for COVID-19 Vaccine Trial - Defense World
Vaxart project agreement change ups funding for oral COVID vaccine candidate - Yahoo Finance
Vaxart secures additional $4.6M for COVID-19 pill vaccine trial - Investing.com Nigeria
Vaxart secures additional $4.6M for COVID-19 pill vaccine trial By Investing.com - Investing.com South Africa
XTX Topco Ltd Boosts Position in Vaxart, Inc. (NASDAQ:VXRT) - Defense World
Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving AverageWhat's Next? - MarketBeat
Vaxart Investors Win Class Cert. Over COVID Shot On 2nd Try - Law360
Vaxart Investors Get Class Status on Second Try Against Insider - Bloomberg Law
Contrasting Tenaya Therapeutics (NASDAQ:TNYA) and Vaxart (NASDAQ:VXRT) - Defense World
No time to wait on development of second-generation vaccines - The Hill
Vaxart (NASDAQ:VXRT) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Akin Gump 'Totally Messed Up' With Texts, Vaxart Judge Says - Law360
Vaxart Hits Key Milestone in Phase 2b Oral COVID Vaccine Trial, Backed by $456M BARDA Deal - StockTitan
Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate - GlobeNewswire
Vaxart, Inc. (NASDAQ:VXRT) Shares Sold by Sio Capital Management LLC - MarketBeat
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside - AOL
VXRT (Vaxart) Enterprise Value : $95.98 Mil (As of Nov. 23, 2024) - GuruFocus.com
B. Riley Has Optimistic Outlook of Vaxart FY2024 Earnings - MarketBeat
COVID-19 vaccine company Vaxart under US federal investigation - Telegrafi
What is B. Riley's Estimate for Vaxart FY2027 Earnings? - MarketBeat
Vaxart Inc Stock (VXRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
2.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):